Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?

Drugs and Aging

Volumn 9, Issue 1, 1996, Pages 1-7

  Van Muiswinkel, F L ^a   Eikelenboom, P ^a  

^a Valeriuskliniek   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYSOSTIGMINE; TACRINE;

ALZHEIMER DISEASE; ASTROCYTE; CHOLINERGIC NERVE; CLINICAL TRIAL; COGNITION; DEMENTIA; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0030018662     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609010-00001     Document Type: Review

References (76)

1. 1. RD Terry E Masliah LA Hansen 1994 Structural basis of the cognitive alterations in Alzheimer’s disease RD Terry R Katzman KL Bick Alzheimer’s disease Raven Press New York 179 96 Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer’s disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer’s disease. New York: Raven Press, 1994: 179–96
2. 2. MMB Breteler JJ Claus CM Duijn van 1992 Epidemiology of Alzheimer’s disease Epidemiol Rev 14 59 82 1289117 1:STN:280:DyaK3s7ntVCnsA%3D%3D Breteler MMB, Claus JJ, van Duijn CM, et al. Epidemiology of Alzheimer’s disease. Epidemiol Rev 1992; 14: 59–82
3. 3. W Max 1993 The economic impact of Alzheimer’s disease Neurology 43 Suppl4 S6 10 Max W. The economic impact of Alzheimer’s disease. Neurology 1993; 43Suppl 4: S6–10
4. 4. K Ogomori T Kitamoto J Tateishi 1989 β-Protein amyloid is widely distributed in the central nervous system of patients with Alzheimer’s disease Am J Pathol 134 234 5 Ogomori K, Kitamoto T, Tateishi J, et al. β-Protein amyloid is widely distributed in the central nervous system of patients with Alzheimer’s disease. Am J Pathol 1989; 134: 234–5
5. 5. X-D Cai TE Golde SG Younkin 1993 Release of excess amyloid β protein from a mutant amyloid β protein precursor Science 259 514 6 8424174 1:CAS:528:DyaK3sXhvV2itbo%3D 10.1126/science.8424174 Cai X-D, Golde TE, Younkin SG. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 1993; 259: 514–6
6. 6. DJ Selkoe 1994 Amyloid β-protein precursor: new dues to the genesis of Alzheimer’s disease Curr Opin Neurobiol 4 708 16 7849528 1:CAS:528:DyaK2MXhvFGjtL0%3D 10.1016/0959-4388(94)90014-0 Selkoe DJ. Amyloid β-protein precursor: new dues to the genesis of Alzheimer’s disease. Curr Opin Neurobiol 1994; 4: 708–16
7. 7. N Suzuki TT Cheung X-D Cai 1994 An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants Science 264 1336 40 8191290 1:CAS:528:DyaK2cXltlWntbY%3D 10.1126/science.8191290 Suzuki N, Cheung TT, Cai X-D, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 1994; 264: 1336–40
8. 8. F Checler 1995 Processing of the β-amyloid precursor protein and its regulation in Alzheimer’s disease J Neurochem 65 1431 44 7561836 1:CAS:528:DyaK2MXotFOluro%3D 10.1046/j.1471-4159.1995.65041431.x Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer’s disease. J Neurochem 1995; 65: 1431–44
9. 9. J Ma A Yee HB Brewer Jr 1994 Amyloid-associated proteins α 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments Nature 372 92 4 7969426 1:CAS:528:DyaK2cXmvFygur0%3D 10.1038/372092a0 Ma J, Yee A, Brewer Jr HB, et al. Amyloid-associated proteins α 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994; 372:92–4
10. 10. WJ Strittmatter AD Roses 1995 Apolipoprotein E and Alzheimer disease Proc Nati Acad Sci USA 92 4725 7 1:CAS:528:DyaK2MXlvFyju7s%3D 10.1073/pnas.92.11.4725 Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Nati Acad Sci USA 1995; 92: 4725–7
11. 11. JM Rozemuller P Eikelenboom FC Stam 1989 A4 protein in Alzheimer’s disease: primary and secondary cellular events in extracellular amyloid deposition J Neuropathol Exper Neurol 48 647 63 10.1097/00005072-198911000-00009 Rozemuller JM, Eikelenboom P, Stam FC, et al. A4 protein in Alzheimer’s disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exper Neurol 1989; 48: 647–63
12. 12. P Eikelenboom FC Stam 1982 Immunoglobulins and complement factors in senile plaques Acta Neuropathol 57 239 42 6812382 1:STN:280:DyaL3s%2FhvV2hug%3D%3D 10.1007/BF00685397 Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol 1982; 57: 239–42
13. 13. CR Abraham DJ Selkoe H Potter 1988 Immunocytochemical identification of the serum protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease Cell 52 487 501 3257719 1:CAS:528:DyaL1cXhsVyhtb0%3D 10.1016/0092-8674(88)90462-X Abraham CR, Selkoe DJ, Potter H. Immunocytochemical identification of the serum protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell 1988; 52: 487–501
14. 14. JM Rozemuller P Eikelenboom ST Pals 1989 Microglial cells around amyloid plaques in Alzheimer’s disease express leucocyte adhesion molecules of the LFA-1 family Neurosci Lett 101 288 92 2549464 1:CAS:528:DyaL1MXltFeisLY%3D 10.1016/0304-3940(89)90547-8 Rozemuller JM, Eikelenboom P, Pals ST, et al. Microglial cells around amyloid plaques in Alzheimer’s disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 1989; 101:288–92
15. 15. J Bauer S Strauss U Schreiter-Gasser 1991 Interleukin 6 and α 2-macroglobulin indicate an acute phase State in Alzheimer’s disease cortices FEBS Lett 285 111 4 1712317 1:CAS:528:DyaK3MXltFamtr8%3D 10.1016/0014-5793(91)80737-N Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin 6 and α 2-macroglobulin indicate an acute phase State in Alzheimer’s disease cortices. FEBS Lett 1991; 285: 111–4
16. 16. EM Frohman TC Frohman S Gupta 1991 Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer’s disease J Neurol Sci 106 105 11 1685745 1:CAS:528:DyaK38Xht1KisL0%3D 10.1016/0022-510X(91)90202-I Frohman EM, Frohman TC, Gupta S, et al. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer’s disease. J Neurol Sci 1991; 106: 105–11
17. 17. PL McGeer J Rogers 1992 Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease Neurology 42 447 9 1736183 1:STN:280:DyaK387ktVKkuw%3D%3D 10.1212/WNL.42.2.447 McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology 1992; 42: 447–9
18. 18. PL McGeer T Kawamata DG Walker 1992 Distribution of clusterin in Alzheimer brain tissue Brain Res 579 337 41 1378350 1:CAS:528:DyaK38XksVGru7Y%3D 10.1016/0006-8993(92)90071-G McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res 1992; 579: 337–41
19. 19. DW Dickson SC Lee LA Mattiace 1993 Microglia and cytokines in neurological disease: with special reference to AIDS and Alzheimer’s disease Glia 7 75 83 8423065 1:STN:280:DyaK3s7jvVOntQ%3D%3D 10.1002/glia.440070113 Dickson DW, Lee SC, Mattiace LA, et al. Microglia and cytokines in neurological disease: with special reference to AIDS and Alzheimer’s disease. Glia 1993; 7: 75–83
20. 20. P Eikelenboom SS Zhan WA Gool van 1994 Inflammatory mechanisms in Alzheimer’s disease Trends Pharmacol Sci 15 447 50 7886816 1:CAS:528:DyaK2MXivFKku7o%3D 10.1016/0165-6147(94)90057-4 Eikelenboom P, Zhan SS, van Gool WA, et al. Inflammatory mechanisms in Alzheimer’s disease. Trends Pharmacol Sci 1994; 15:447–50
21. 21. P Eikelenboom SS Zhan W Kamphorst 1994 Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer’s disease Virchows Arch 424 421 7 7515758 1:STN:280:DyaK2c3msV2mtQ%3D%3D 10.1007/BF00190565 Eikelenboom P, Zhan SS, Kamphorst W, et al. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer’s disease. Virchows Arch 1994; 424: 421–7
22. 22. WST Griffin JG Sheng GW Roberts 1995 Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution J Neuropathol Exper Neurol 54 276 81 1:STN:280:DyaK2M7ot1WltA%3D%3D 10.1097/00005072-199503000-00014 Griffin WST, Sheng JG, Roberts GW, et al. Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J Neuropathol Exper Neurol 1995; 54: 276–81
23. 23. R Veerhuis P Valk Van der I Janssen 1995 Complement activation in amyloid plaques in Alzheimer’s disease brains does not proceed further than C3 Virchows Arch 426 603 10 7655742 1:CAS:528:DyaK2MXosl2ls7o%3D 10.1007/BF00192116 Veerhuis R, Van der Valk P, Janssen I, et al. Complement activation in amyloid plaques in Alzheimer’s disease brains does not proceed further than C3. Virchows Arch 1995; 426: 603–10
24. 24. R Veerhuis I Janssen CE Hack 1996 Early complement components in Alzheimer’s disease brains Acta Neuropathol 91 53 60 8773146 1:CAS:528:DyaK28XhtFyksr4%3D 10.1007/s004019570001 Veerhuis R, Janssen I, Hack CE, et al. Early complement components in Alzheimer’s disease brains. Acta Neuropathol 1996; 91: 53–60
25. 25. S-S Zhan R Veerhuis W Kamphorst 1995 Distribution of beta amyloid associated proteins in plaques in Alzheimer’s disease and in the non-demented elderly Neurodegeneration 4 291 7 8581561 1:STN:280:DyaK287jtVyksw%3D%3D 10.1016/1055-8330(95)90018-7 Zhan S-S, Veerhuis R, Kamphorst W, et al. Distribution of beta amyloid associated proteins in plaques in Alzheimer’s disease and in the non-demented elderly. Neurodegeneration 1995; 4: 291–7
26. 26. IRA Mackenzie CH Hao DG Munoz 1995 Microglia in senile plaque formation Neurobiol Aging 16 797 804 8532113 1:STN:280:DyaK287gvVCqsw%3D%3D 10.1016/0197-4580(95)00092-S Mackenzie IRA, Hao CH, Munoz DG. Microglia in senile plaque formation. Neurobiol Aging 1995; 16: 797–804
27. 27. J Rogers J Luber-Narod SD Styren 1988 Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease Neurobiol Aging 9 339 49 3263583 1:STN:280:DyaL1M%2FktVCgtg%3D%3D 10.1016/S0197-4580(88)80079-4 Rogers J, Luber-Narod J, Styren SD, et al. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging 1988; 9: 339–49
28. 28. M Huell S Strauss B Volk 1995 Interleukin-6 is present in early stages of plaque formations and is restricted to the brains of Alzheimer’s disease patients Acta Neuropathol 89 544 51 7676810 1:STN:280:DyaK2MvgslarsA%3D%3D 10.1007/BF00571510 Huell M, Strauss S, Volk B, et al. Interleukin-6 is present in early stages of plaque formations and is restricted to the brains of Alzheimer’s disease patients. Acta Neuropathol 1995; 89: 544–51
29. 29. CA Colton DL Gilbert 1993 Microglia, an in vivo source of reactive oxygen species in the brain FJ Seil Advances in Neurology. Vol. 59 Raven Press New York 321 6 Colton CA, Gilbert DL. Microglia, an in vivo source of reactive oxygen species in the brain. In: Seil FJ, editor. Advances in Neurology. Vol. 59. New York: Raven Press, 1993: 321–6
30. 30. S Haga K Ikeda M Sato 1993 Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglia cells Brain Res 601 88 94 8431789 1:CAS:528:DyaK3sXhvV2lsbY%3D 10.1016/0006-8993(93)91698-R Haga S, Ikeda K, Sato M, et al. Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglia cells. Brain Res 1993; 601: 88–94
31. 31. A Klegeris DG Walker PL McGeer 1994 Activation of macrophages by Alzheimer β amyloid peptide Biochem Biophys Res Commun 199 984 91 7510964 1:CAS:528:DyaK2cXitFCgu70%3D 10.1006/bbrc.1994.1326 Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer β amyloid peptide. Biochem Biophys Res Commun 1994; 199: 984–91
32. 32. D Giulian LJ Haverkamp J Li 1995 Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain Neurochem Int 27 119 37 7655344 1:CAS:528:DyaK2MXmsFyltr8%3D 10.1016/0197-0186(95)00067-I Giulian D, Haverkamp LJ, Li J, et al. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 1995; 27: 119–37
33. 33. FL Muiswinkel Van R Veerhuis P Eikelenboom 1996 Amyloid β protein (Aβ) primes cultured rat microglial cells for an enhanced phorbol-myristate-acetate induced respiratory burst activity J Neurochem 66 2468 76 8632171 10.1046/j.1471-4159.1996.66062468.x Van Muiswinkel FL, Veerhuis R, Eikelenboom P. Amyloid β protein (Aβ) primes cultured rat microglial cells for an enhanced phorbol-myristate-acetate induced respiratory burst activity. J Neurochem 1996; 66: 2468–76
34. 34. DG Walker SU Kim PL McGeer 1995 Complement and cytokine gene expression in cultured microglia derived from postmortem human brains J Neurosci Res 40 478 93 7616608 1:CAS:528:DyaK2MXktF2rtr8%3D 10.1002/jnr.490400407 Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 1995; 40: 478–93
35. 35. LM Shaffer MD Dority R Gupta-Bansal 1995 Amyloid β protein (Aβ) removal by neuroglial cells in culture Neurobiol Aging 16 737 45 8532106 1:CAS:528:DyaK2MXpsVShu7Y%3D 10.1016/0197-4580(95)00055-J Shaffer LM, Dority MD, Gupta-Bansal R, et al. Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiol Aging 1995; 16:737–45
36. 36. JB Davis HF McMurray D Schubert 1992 The amyloid beta-protein of AD is chemotactic for mononuclear phagocytes Biochem Biophys Res Commun 189 1096 100 1472019 1:CAS:528:DyaK3sXlsl2jsg%3D%3D 10.1016/0006-291X(92)92317-Q Davis JB, McMurray HF, Schubert D. The amyloid beta-protein of AD is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun 1992; 189: 1096–100
37. 37. RB Banati J Gehrmann P Schubert 1993 Cytotoxicity of microglia Glia 7 111 8 8423058 1:STN:280:DyaK3s7jvVOgug%3D%3D 10.1002/glia.440070117 Banati RB, Gehrmann J, Schubert P, et al. Cytotoxicity of microglia. Glia 1993; 7: 111–8
38. 38. PL McGeer T Kawamata DG Walker 1993 Microglia in degenerative neurological disease Glia 7 84 92 8423066 1:STN:280:DyaK3s7jvVOnug%3D%3D 10.1002/glia.440070114 McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia 1993; 7: 84–92
39. 39. J Rogers NR Cooper S Webster 1992 complement activation by β-amyloid in Alzheimer’s disease Proc Nati Acad Sci USA 89 10016 20 1:CAS:528:DyaK3sXitVektg%3D%3D 10.1073/pnas.89.21.10016 Rogers J, Cooper NR, Webster S, et al. complement activation by β-amyloid in Alzheimer’s disease. Proc Nati Acad Sci USA 1992; 89: 10016–20
40. 40. H Jiang D Burdick CG Glabe 1994 β-amyloid activates complement by binding to a specifie region of the collage-like domain of the Clq Achain J Immunol 152 5050 9 8176223 1:CAS:528:DyaK2cXksFGmtLY%3D Jiang H, Burdick D, Glabe CG, et al. β-amyloid activates complement by binding to a specifie region of the collage-like domain of the Clq Achain. J Immunol 1994; 152: 5050–9
41. 41. S Webster S O’Barr J Rogers 1994 Enhanced aggregation and β structure of amyloid β peptide after coincubation with Clq J Neurosci Res 39 448 56 7884823 1:CAS:528:DyaK2cXmvFygu78%3D 10.1002/jnr.490390412 Webster S, O’Barr S, Rogers J. Enhanced aggregation and β structure of amyloid β peptide after coincubation with Clq. J Neurosci Res 1994; 39: 448–56
42. 42. AR Korotzer J Watt D Cribbs 1995 Cultured rat microglia express Clq and receptor Clq: implications for amyloid effects on microglia Exper Neurol 134 214 21 1:CAS:528:DyaK2MXptFSju78%3D 10.1006/exnr.1995.1051 Korotzer AR, Watt J, Cribbs D, et al. Cultured rat microglia express Clq and receptor Clq: implications for amyloid effects on microglia. Exper Neurol, 1995; 134: 214–21
43. 43. SA Johnson M Lampert-Etchells GM Pasinetti 1992 Complement mRNA in the mammalian brain: responses to Alzheimer’s disease and experimental brain lesioning Neurobiol Aging 13 641 8 1362796 1:CAS:528:DyaK3sXitFSlt74%3D 10.1016/0197-4580(92)90086-D Johnson SA, Lampert-Etchells M, Pasinetti GM, et al. Complement mRNA in the mammalian brain: responses to Alzheimer’s disease and experimental brain lesioning. Neurobiol Aging 1992; 13: 641–8
44. 44. A Lorenzo BA Yankner 1994 Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red Proc Natl Acad Sci USA 91 12243 7 7991613 1:CAS:528:DyaK2MXisF2jsL4%3D 10.1073/pnas.91.25.12243 Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91: 12243–7
45. 45. CJ Pike AJ Walencewicz-Wasserman J Kosmoski 1995 Structure-activity analysis of β-amyloid peptides: contributions of the β25–35 region to aggregation and neurotoxicity J Neurochem 64 253 65 7798921 1:CAS:528:DyaK2MXislSjsbg%3D 10.1046/j.1471-4159.1995.64010253.x Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, et al. Structure-activity analysis of β-amyloid peptides: contributions of the β25–35 region to aggregation and neurotoxicity. J Neurochem, 1995; 64: 253–65
46. 46. J Schultz J Schaller M McKinley 1994 Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism Neurosci Lett 175 99 102 7970221 1:CAS:528:DyaK2MXitlKnsw%3D%3D 10.1016/0304-3940(94)91088-X Schultz J, Schaller J, McKinley M, et al. Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism. Neurosci Lett, 1994; 175: 99–102
47. 47. MJ Knapp DS Knopman PR Solomon 1994 A 30-week, randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease JAMA 271 985 91 8139083 1:STN:280:DyaK2c7oslWmsQ%3D%3D 10.1001/jama.1994.03510370037029 Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week, randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91
48. 48. E Mohr T Mendis IN Rusk 1994 Neurotransmitter replacement therapy in Alzheimer’s disease J Psychiatry Neurosci 19 17 23 7908537 1:STN:280:DyaK2c7pvVakug%3D%3D Mohr E, Mendis T, Rusk IN, et al. Neurotransmitter replacement therapy in Alzheimer’s disease. J Psychiatry Neurosci 1994; 19: 17–23
49. 49. M Rossor LL Iveren 1986 Non-cholinergic neurotransmitter abnormalities in Alzheimer’s disease Br Med Bull 42 70 4 2869818 1:CAS:528:DyaL28Xht1Ons7w%3D Rossor M, Iveren LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer’s disease. Br Med Bull 1986; 42: 70–4
50. 50. PS Aisen KL Davis 1994 Inflammatory mechanisms in Alzheimer’s disease: implications for therapy Am J Psychiatry 151 1105 13 7518651 1:STN:280:DyaK2czhtFemsQ%3D%3D Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry 1994; 151: 1105–13
51. 51. LM Bierer V Haroutunian S Gabriel 1995 Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits J Neurochem 64 749 60 7830069 1:CAS:528:DyaK2MXjtFymtrw%3D 10.1046/j.1471-4159.1995.64020749.x Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749–60
52. 52. AAJ O’Brien CJ Bulpitt 1995 The effects of ACE inhibitors on cognitive function Drugs Aging 6 173 80 7620231 10.2165/00002512-199506030-00001 O’Brien AAJ, Bulpitt CJ. The effects of ACE inhibitors on cognitive function. Drugs Aging 1995; 6: 173–80
53. 53. ML Jenkinson MR Bliss AT Brain 1989 Rheumatoid arthritis and senile dementia of the Alzheimer’s type Br J Rheumatol 28 86 8 2917245 1:STN:280:DyaL1M7jsFChuw%3D%3D 10.1093/rheumatology/28.1.86-b Jenkinson ML, Bliss MR, Brain AT, et al. Rheumatoid arthritis and senile dementia of the Alzheimer’s type. Br J Rheumatol 1989; 28: 86–8
54. 54. PL McGeer E McGeer J Rogers 1990 Anti-inflammatory drugs and Alzheimer disease Lancet 335 1037 1970087 1:STN:280:DyaK3c3itVWrsg%3D%3D 10.1016/0140-6736(90)91101-F [letter] McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease [letter]. Lancet 1990; 335: 1037
55. 55. Canadian study of health and aging. The Canadian study of health and aging: risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–80
56. 56. JCS Breitner BA Gau KA Welsh 1994 Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study Neurology 44 227 32 8309563 1:STN:280:DyaK2c7kt1yqtA%3D%3D 10.1212/WNL.44.2.227 Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44: 227–32
57. 57. JCS Breitner KA Welsh MJ Helms 1995 Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H 2 blocking drugs Neurobiol Aging 16 523 30 8544901 1:STN:280:DyaK287ltleqsQ%3D%3D 10.1016/0197-4580(95)00049-K Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H 2 blocking drugs. Neurobiol Aging 1995; 16: 523–30
58. 58. K Andersen LJ Launer A Ott 1995 Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study Neurology 45 1441 5 7644037 1:CAS:528:DyaK2MXns1Sis78%3D 10.1212/WNL.45.8.1441 Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 1995; 45: 1441–5
59. 59. J Rogers LC Kirby SR Hempelman 1993 Clinical trial of indomethacin in Alzheimer’s disease Neurology 43 1609 11 8351023 1:STN:280:DyaK3szlsVGrtw%3D%3D 10.1212/WNL.43.8.1609 Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11
60. 60. JB Rich DX Rasmusson MF Folstein 1995 Nonsteroidal antiinflammatory drugs in Alzheimer’s disease Neurology 45 51 5 7824134 1:STN:280:DyaK2M7isVGlsA%3D%3D 10.1212/WNL.45.1.51 Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal antiinflammatory drugs in Alzheimer’s disease. Neurology 1995; 45:51–5
61. 61. L Girgis P Brooks 1994 Nonsteriodal anti-inflammatory drugs: differential use in older patients Drugs Aging 4 101 12 8186538 1:STN:280:DyaK2c3ktlWitw%3D%3D 10.2165/00002512-199404020-00003 Girgis L, Brooks P. Nonsteriodal anti-inflammatory drugs: differential use in older patients. Drugs Aging 1994; 4: 101–12
62. 62. RH Jones CL Tait 1995 Gastrointestinal side-effects of NSAIDs in the community Br J Clin Pract 49 67 70 7779646 1:STN:280:DyaK2M3pvVGqtA%3D%3D Jones RH, Tait CL. Gastrointestinal side-effects of NSAIDs in the community. Br J Clin Pract 1995; 49: 67–70
63. 63. PM Brooks RO Day 1991 Nonsteroidal antiinflammatory drugs: differences and similarities N Engl J Med 324 1716 25 2034249 1:STN:280:DyaK3M3jvV2isQ%3D%3D 10.1056/NEJM199106133242407 Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med 1991; 324: 1716–25
64. 64. KG Saag LM Rubenstein Chrischilles 1995 Nonsteriodal antiinflammatory drugs and cognitive decline in the elderly J Rheumatol 22 2142 7 8596158 1:STN:280:DyaK287lslOqug%3D%3D Saag KG, Rubenstein LM, Chrischilles, et al. Nonsteriodal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995; 22: 2142–7
65. 65. M Seitz P Loetscher B Dewald 1994 Immunosuppressive drugs and their complications Drug Ther Bull 32 66 70 10.1136/dtb.1994.32966 Seitz M, Loetscher P, Dewald B, et al. Immunosuppressive drugs and their complications. Drug Ther Bull 1994; 32: 66–70
66. 66. CA Wilmot SR Sahasrabudhe GE Ringheim 1995 β-amyloid, cytokines and other potential strategies for modifying the pathophysiology of Alzheimer’s disease NR Cutler CG Gottfries K Siegfried Alzheimer’s disease: clinical and treatment perspectives John Wiley and Sons Chichester 117 50 Wilmot CA, Sahasrabudhe SR, Ringheim GE, et al. β-amyloid, cytokines and other potential strategies for modifying the pathophysiology of Alzheimer’s disease. In: Cutler NR, Gottfries CG, Siegfried K, editors. Alzheimer’s disease: clinical and treatment perspectives. Chichester: John Wiley and Sons, 1995: 117–50
67. 67. Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol Aging. In press
68. 68. V-Y Lee R Daughenbaugh JQ Trojanowski 1994 Microtubule stabilizing drugs for the treatment of Alzheimer’s disease: a position paper Neurobiol Aging 15 S87 9 7700471 10.1016/0197-4580(94)90179-1 Lee VM-Y, Daughenbaugh R, Trojanowski JQ. Microtubule stabilizing drugs for the treatment of Alzheimer’s disease: a position paper. Neurobiol Aging 1994; 15: S87–9
69. 69. A Furuta DL Price CA Pardo 1995 Localization of Superoxide dismutases in Alzheimer’s disease and Down’s syndrome neocortex and hippocampus Am J Pathol 146 357 67 7856748 1:STN:280:DyaK2M7mtVWgtg%3D%3D Furuta A, Price DL, Pardo CA, et al. Localization of Superoxide dismutases in Alzheimer’s disease and Down’s syndrome neocortex and hippocampus. Am J Pathol 1995; 146: 357–67
70. 70. D Games D Adams R Alessandrini 1995 Alzheimer-type neuropathology in transgenic mice overexpressing V717F betaamyloid precursor protein Nature 373 523 7 7845465 1:CAS:528:DyaK2MXjs1Wns7w%3D 10.1038/373523a0 Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F betaamyloid precursor protein. Nature 1995; 373: 523–7
71. 71. T Arendt M Holzer R Fruth 1995 Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2a Neuroscience 69 691 8 8596639 1:CAS:528:DyaK2MXpsVGrsr4%3D 10.1016/0306-4522(95)00347-L Arendt T, Holzer M, Fruth R, et al. Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2a. Neuroscience 1995; 69: 691–8
72. 72. JR Vane 1995 NSAIDs, COX-2 inhibitors, and the gut Lancet 346 1105 6 7564818 1:STN:280:DyaK28%2FisF2mtA%3D%3D 10.1016/S0140-6736(95)92770-0 [letter] Vane JR. NSAIDs, COX-2 inhibitors, and the gut [letter]. Lancet 1995; 346: 1105–6
73. 73. SN Elliott W McKnight G Cirino 1995 A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats Gastroenterology 109 524 30 7615202 1:CAS:528:DyaK2MXntlCgtb8%3D 10.1016/0016-5085(95)90341-0 Elliott SN, McKnight W, Cirino G, et al. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524–30
74. 74. O Rott B Fleischer E Cash 1994 Interleukin-10 prevents experimental allergic encephalitis in rats Eur J Immunol 24 1434 40 7515815 1:CAS:528:DyaK2cXkvVSltLs%3D 10.1002/eji.1830240629 Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalitis in rats. Eur J Immunol 1994; 24: 1434–40
75. 75. D Burger J-M Dayer 1995 Inhibitory cytokines and cytokine inhibitors Neurology 45 S39 43 7783910 1:STN:280:DyaK2Mzgtleisw%3D%3D 10.1212/WNL.45.6_Suppl_6.S39 Burger D, Dayer J-M. Inhibitory cytokines and cytokine inhibitors. Neurology 1995; 45: S39–43
76. 76. F Salaffi M Carotti A Sartini 1995 A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis Clin Exp Rheumatol 13 23 8 7774099 1:STN:280:DyaK2M3pt1Cguw%3D%3D Salaffi F, Carotti M, Sartini A, et al. A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 23–8